IL6 and hepatocellular carcinoma: Thirty control cases, 55 liver cirrhosis patients without HCC, and 75 liver cirrhosis cases with HCC were evaluated in the current trial; AFP (p < 0.001) and IL-6 (p < 0.001) were found to be significantly higher among HCC cases, as compared with control group.